These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


161 related items for PubMed ID: 15225866

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J.
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
    Alou L, Aguilar L, Sevillano D, Giménez MJ, Cafini F, Valero E, Relaño MT, Prieto J.
    J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I, Cars O, Löwdin E.
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 11. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation.
    Prieto J, Giménez MJ, Balcabao IP, Gómez-Lus ML, Aguilar L.
    J Chemother; 1999 Oct; 11(5):345-8. PubMed ID: 10632379
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG, Derkatch S, Laing N, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [Abstract] [Full Text] [Related]

  • 19. [The postantibiotic effect of amoxicillin/clavulanic acid on Streptococcus pneumoniae strains of different serotypes and penicillin sensitivity].
    García Y, Gómez MJ, Ramos MC, Gómez-Lus ML, Prieto J.
    Rev Esp Quimioter; 1998 Jun; 11(2):157-60. PubMed ID: 9795302
    [Abstract] [Full Text] [Related]

  • 20. Impact of co-amoxiclav on polymorphonuclear granulocytes from chronic hemodialysis patients.
    Cuffini AM, Tullio V, Giacchino F, Mandras N, Scalas D, Belardi P, Merlino C, Carlone NA.
    Am J Kidney Dis; 2001 Jun; 37(6):1253-9. PubMed ID: 11382696
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.